Biomarkers in Tissue Samples From Patients With Ewing Sarcoma

Analysis of GGAA-Microsatellites in Ewing Sarcoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01480518

Enrollment

166

Registered

2011-11-29

Start date

2011-12-31

Completion date

2012-01-31

Last updated

2015-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Keywords

localized Ewing sarcoma/peripheral primitive neuroectodermal tumor

Brief summary

RATIONALE: Studying samples of tissue in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers in tissue samples from patients with Ewing sarcoma.

Detailed description

OBJECTIVES: * To describe the spectrum of GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing sarcoma tumor specimens. * To determine if there are differences in GGAA-microsatellite polymorphisms in genomic DNA prepared from Ewing sarcoma tumor specimens as compared to non-afflicted European and African normal genomic DNA. * To determine if GGAA-microsatellite polymorphisms at specific loci in genomic DNA prepared from Ewing's sarcoma tumor specimens correlates with disease outcome in patients treated on COG protocol AEWS0031. * To determine whether whole-genome amplification introduces alterations in GGAA-microsatellites as compared to non-amplified genomic DNA. OUTLINE: Genomic PCR is used to amplify the microsatellites in the NR0B1 and GSTM4 promoters. In addition to determining microsatellite size, each microsatellite is sequenced following cloning into the pCR4 vector (Invitrogen) using standard topoisomerase cloning protocols.

Interventions

OTHERlaboratory biomarker analysis

GENETICDNA analysis

GENETICcomparative genomic hybridization

GENETICgene expression analysis

GENETICmutation analysis

GENETICpolymerase chain reaction

GENETICpolymorphic microsatellite marker analysis

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 50 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Specimens from patients with Ewing sarcoma used for protocol COG-AEWS08B1 * Obtained from patient samples taken from patients enrolled on COG-AEWS0031 * Whole genome-amplified DNA will be used PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Event-free survival	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026